צמיחת הכנסות ב-12 חודשים נגררים: LakeShore Biopharma Co. (LSB)

LakeShore Biopharma Co. (LSB) is fighting for survival amid internal conflicts and the abandonment of mergers, focusing instead on rabies vaccine sales. The year-over-year relative revenue growth rate (12 months) visualizes these challenges, with the current figure standing at . Risks are mitigated by outsourcing production and marketing in China to partners, as well as an advanced cold-chain logistics network that ensures high margins.
ysbiopharm.com (LSB) - פילוחי מדדים ודוחות פיננסיים

LakeShore Biopharma Co. (LSB) maintains a narrow specialization in rabies vaccines, rendering its revenue dependent on Chinese government procurement. This dependency is directly reflected in the year-over-year (TTM) commercial revenue growth trend, which smooths quarterly gaps via a rolling window. This metric measures the pace of business expansion, revealing hidden stagnations or sales accelerations. Trend analysis allows for the differentiation of temporary dips from a systemic demand crisis. By studying the year-over-year (TTM) commercial revenue growth, an investor assesses the resilience of cash flow against regulatory risks.